RCT | Solanezumab fails to slow cognitive decline in preclinical Alzheimer’s disease

Trial of Solanezumab in Preclinical Alzheimer’s Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Related:

RCT | Donanemab slows early symptomatic Alzheimer’s progression, but raises serious safety concerns

RCT | Lecanemab slows cognitive decline in early Alzheimer’s disease but raises safety concerns

Commentary on Twitter

Original Article: Trial of Solanezumab in Preclinical Alzheimer’s Disease (A4 trial) https://t.co/lCXsVoiP8i #AAIC23 pic.twitter.com/e8DplR27yd

— NEJM (@NEJM) July 18, 2023